KBP Biosciences

Novo Nordisk
Oct 16, 2023

Novo Nordisk to buy hypertension drug for $1.3B

The medication from KBP Biosciences – which is based in Singapore with U.S. headquarters in Princeton – also has the potential to treat cardiovascular and kidney disease, the companies said.